Treatment of prostate cancer by hypofractionated radiotherapy

Abstract

Technological advances in radiation therapy delivery have permitted the use of high dose per fraction radiotherapy for early stage prostate cancer. Level I evidence supporting the safety and efficasy of hypofractionated radiotherapy is evolving. Moderate and extreme hypofractionation regimens show promising cancer control but long term results of noninferiority studies of both modalities are required before use in routine treatment as standard of care.

Proceedings in oncology: Aren’t we back to the future?

“…Sefik Igdem and Sevil Bavbek summarized the recent advances in hypofractionated radiotherapy for local and management of castrate-resistant prostate cancer [4,5].…”